Literature DB >> 30593971

Magnetic Resonance Imaging Parameters and Their Impact on Survival of Patients with Glioblastoma: Tumor Perfusion Predicts Survival.

Bob L Hou1, Sijin Wen2, Gennadiy A Katsevman3, Hui Liu2, Ogaga Urhie4, Ryan C Turner5, Jeffrey Carpenter1, Sanjay Bhatia5.   

Abstract

BACKGROUND: Many prognostic factors influence overall survival (OS) of patients with glioblastoma. Despite gross total resection and Stupp protocol adherence, many patients have poor survival. Perfusion magnetic resonance imaging may assist in diagnosis, treatment monitoring, and prognostication.
METHODS: This retrospective study of 36 patients with glioblastoma assessed influence of preoperative magnetic resonance imaging parameters reflecting tumor cell density and vascularity and patient age on OS.
RESULTS: The area under curve based on optimal receiver operating characteristic curves for the perfusion parameters normalized relative tumor blood volume (n_rTBV) and normalized relative tumor blood flow (n_rTBF) were 0.92 and 0.89, respectively, and the highest among all imaging parameters and age. OS showed strongly negative correlations with corrected n_rTBV (R = -0.70; P < 0.001) and n_rTBF (R = -0.67; P < 0.001). The Cox model, which included age and imaging parameters, demonstrated that n_rTBV and n_rTBF were most predictive of OS, with hazard ratios of 5.97 (P = 0.0001) and 8.76 (P = 0.0001), respectively, compared with 1.63 (P = 0.19) for age. Eighteen patients with corrected n_rTBV ≤2.5 (best cutoff value) had a median OS of 15.1 months (95% confidence interval (CI), 11.34-21.25) compared with 2.8 months (95% CI, 1.48-4.03; P < 0.001) for 18 patients with corrected n_rTBV >2.5. Twenty-four patients with n_rTBF ≤2.79 had a median OS of 12 months (95% CI, 10.46-17.9) compared with 2.8 months for 12 patients with n_rTBF >2.79 (95% CI, 1.31-4.2; P < 0.001).
CONCLUSIONS: The dominant predictors of OS are normalized perfusion parameters n_rTBV and n_rTBF. Preoperative perfusion imaging may be used as a surrogate to predict glioblastoma aggressiveness and survival independent of treatment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anatomic MRI; Diffusion MRI; Glioblastoma; OS; Overall survival; Perfusion MRI; TBF; TBV; Tumor blood flow; Tumor blood volume

Year:  2018        PMID: 30593971      PMCID: PMC6597330          DOI: 10.1016/j.wneu.2018.12.085

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  34 in total

1.  Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.

Authors:  Alissa A Thomas; Julio Arevalo-Perez; Thomas Kaley; John Lyo; Kyung K Peck; Weiji Shi; Zhigang Zhang; Robert J Young
Journal:  J Neurooncol       Date:  2015-08-15       Impact factor: 4.130

Review 2.  Advanced magnetic resonance imaging of the physical processes in human glioblastoma.

Authors:  Jayashree Kalpathy-Cramer; Elizabeth R Gerstner; Kyrre E Emblem; Ovidiu Andronesi; Bruce Rosen
Journal:  Cancer Res       Date:  2014-09-01       Impact factor: 12.701

3.  Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.

Authors:  Rajan Jain; Laila Poisson; Jayant Narang; David Gutman; Lisa Scarpace; Scott N Hwang; Chad Holder; Max Wintermark; Rivka R Colen; Justin Kirby; John Freymann; Daniel J Brat; Carl Jaffe; Tom Mikkelsen
Journal:  Radiology       Date:  2012-12-13       Impact factor: 11.105

4.  MRI perfusion in determining pseudoprogression in patients with glioblastoma.

Authors:  Robert J Young; Ajay Gupta; Akash D Shah; Jerome J Graber; Timothy A Chan; Zhigang Zhang; Weiji Shi; Kathryn Beal; Antonio M Omuro
Journal:  Clin Imaging       Date:  2012-06-08       Impact factor: 1.605

5.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

6.  Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery.

Authors:  Nicholas F Marko; Robert J Weil; Jason L Schroeder; Frederick F Lang; Dima Suki; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

7.  Quantitative Assessment of Invasion of High-Grade Gliomas Using Diffusion Tensor Magnetic Resonance Imaging.

Authors:  Zonggang Hou; Xu Cai; Huan Li; Chun Zeng; Jiangfei Wang; Zhixian Gao; Mingyu Zhang; Weibei Dou; Ning Zhang; Liwei Zhang; Jian Xie
Journal:  World Neurosurg       Date:  2018-02-23       Impact factor: 2.104

8.  Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.

Authors:  A Gupta; R J Young; A D Shah; A D Schweitzer; J J Graber; W Shi; Z Zhang; J Huse; A M P Omuro
Journal:  Clin Neuroradiol       Date:  2014-01-29       Impact factor: 3.649

9.  Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.

Authors:  Inseon Ryoo; Seung Hong Choi; Ji-Hoon Kim; Chul-Ho Sohn; Soo Chin Kim; Hwa Seon Shin; Jeong A Yeom; Seung Chai Jung; A Leum Lee; Tae Jin Yun; Chul-Kee Park; Sung-Hye Park
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.

Authors:  Warren Chang; Whitney B Pope; Robert J Harris; Anthony J Hardy; Kevin Leu; Reema R Mody; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  Tomography       Date:  2015-09
View more
  1 in total

1.  MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas.

Authors:  Elies Fuster-Garcia; David Lorente Estellés; María Del Mar Álvarez-Torres; Javier Juan-Albarracín; Eduard Chelebian; Alex Rovira; Cristina Auger Acosta; Jose Pineda; Laura Oleaga; Enrique Mollá-Olmos; Silvano Filice; Paulina Due-Tønnessen; Torstein R Meling; Kyrre E Emblem; Juan M García-Gómez
Journal:  Eur Radiol       Date:  2020-10-01       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.